menu
    • menu
    [{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Knight Therapeutics \/ Knight Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Knight Therapeutics"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"TherapeuticsMD","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Estradiol","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ TherapeuticsMD","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ TherapeuticsMD"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ Knight Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Knight Therapeutics"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ Knight Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Knight Therapeutics"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Profounda Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Miltefosine","moa":"Cytochrome c oxidase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ Knight Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Knight Therapeutics \/ Knight Therapeutics"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Knight Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rivastigmine Tartrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rivastigmine Tartrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ Knight Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Knight Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Knight Therapeutics

    Menu

    Knight Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isavuconazonium Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Basilea Pharmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cresemba® Sales in Latin America Trigger First Sales Milestone Payment to Basilea

                            Details : Knight will commercialize Cresemba (isavuconazole sulfate) in Latin America, an azole antifungal for treating adult patients with invasive aspergillosis, licensed for regional distribution.

                            Brand Name : Cresemba

                            Molecule Type : Small molecule

                            Upfront Cash : $11.2 million

                            January 19, 2024

                            Lead Product(s) : Isavuconazonium Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Basilea Pharmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivastigmine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

                            Details : Exelon Patch (rivastigmine transdermal system) is a class of medications called cholinesterase inhibitors, which is used to manage and treat neurodegenerative disease, specifically dementia, in patients with Alzheimer and Parkinson disease.

                            Brand Name : Exelon

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 15, 2022

                            Lead Product(s) : Rivastigmine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivastigmine Tartrate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

                            Details : Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..

                            Brand Name : Exelon

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 15, 2022

                            Lead Product(s) : Rivastigmine Tartrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivastigmine Tartrate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia

                            Details : Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..

                            Brand Name : Exelon

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 01, 2022

                            Lead Product(s) : Rivastigmine Tartrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Miltefosine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Profounda Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Profounda Orphan Drug Designation Approval for treatment of Treatment of Invasive Candidiasis with ...

                            Details : Miltefosine is an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europ...

                            Brand Name : Impavido

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 08, 2021

                            Lead Product(s) : Miltefosine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Profounda Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivastigmine Tartrate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : $180.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Knight Therapeutics Announces Closing of Previously Announced Acquisition and Exclusive License to Exelon® in...

                            Details : Knight Therapeutics has acquired exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsules and Solution) in Canada and Latin America, as well as an exclusive license to use the intellectual property and the Exelon trademark,...

                            Brand Name : Exelon

                            Molecule Type : Small molecule

                            Upfront Cash : $168.0 million

                            May 26, 2021

                            Lead Product(s) : Rivastigmine Tartrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : $180.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivastigmine Tartrate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : $180.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Knight Therapeutics to Acquire Regional Rights to Exelon®

                            Details : Exelon (rivastigmine) is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries. Exelon is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alz...

                            Brand Name : Exelon

                            Molecule Type : Small molecule

                            Upfront Cash : $168.0 million

                            April 23, 2021

                            Lead Product(s) : Rivastigmine Tartrate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : $180.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Estradiol,Progesterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : TherapeuticsMD

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®

                            Details : BIJUVA is a once-daily combination of estradiol and progesterone in a single oral capsule that will be available in two strengths in Canada indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an in...

                            Brand Name : Bijuva

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2020

                            Lead Product(s) : Estradiol,Progesterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : TherapeuticsMD

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neratinib,Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® to Treat HER2-Posit...

                            Details : The SNDS is supported by the results of the Phase IIINALA trial, a randomized controlled trial of neratinib plus capecitabine versus Tykerb® (lapatinib) plus capecitabine in HER2-positive metastatic breast cancer patients previously treated with = 2 HER...

                            Brand Name : Nerlynx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 03, 2020

                            Lead Product(s) : Neratinib,Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Knight Therapeutics

                            Canada arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®

                            Details : In Canada, IMVEXXY is approved for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA).

                            Brand Name : Imvexxy

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 25, 2020

                            Lead Product(s) : Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth